MDPV and α-PVP use in humans: The twisted sisters

[1]  K. Rice,et al.  Reinforcing effects of abused ‘bath salts’ constituents 3,4-methylenedioxypyrovalerone and &agr;-pyrrolidinopentiophenone and their enantiomers , 2017, Behavioural pharmacology.

[2]  B. Blough,et al.  Cocaine‐like discriminative stimulus effects of alpha‐pyrrolidinovalerophenone, methcathinone and their 3,4‐methylenedioxy or 4‐methyl analogs in rhesus monkeys , 2017, Addiction biology.

[3]  D. Zuba,et al.  Alpha-PVP as an active component of herbal highs in Poland between 2013 and 2015. , 2017, Drug testing and analysis.

[4]  C. Rabe,et al.  Synthetic cathinones in Southern Germany – characteristics of users, substance-patterns, co-ingestions, and complications , 2017, Clinical toxicology.

[5]  C. Stanciu,et al.  Withdrawn: The Behavioral Profile of methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (PVP) - A Systematic Review. , 2017, Current drug abuse reviews.

[6]  T. Janus,et al.  Fatal Intoxication with α‐PVP, a Synthetic Cathinone Derivative , 2017, Journal of forensic sciences.

[7]  C. Jang,et al.  Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents , 2017, Psychopharmacology.

[8]  D. Cooper,et al.  Multi‐organ dysfunction due to bath salts: are we aware of this entity? , 2017, Internal medicine journal.

[9]  L. Karila,et al.  [Synthetic cannabinoids: A new addiction matrix]. , 2017, Presse medicale.

[10]  A. Benyamina,et al.  [Synthetic cannabinoids: A new addiction matrix]. , 2017, Presse medicale.

[11]  Kurt R. Lehner,et al.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. , 2017, Current topics in behavioral neurosciences.

[12]  J. Zawilska,et al.  α-Pyrrolidinophenones: a new wave of designer cathinones , 2017, Forensic Toxicology.

[13]  E. Thorndike,et al.  Pharmacological mechanisms underlying the cardiovascular effects of the “bath salt” constituent 3,4‐methylenedioxypyrovalerone (MDPV) , 2016, British journal of pharmacology.

[14]  C. White.  Mephedrone and 3,4‐Methylenedioxypyrovalerone (MDPV): Synthetic Cathinones With Serious Health Implications , 2016, Journal of clinical pharmacology.

[15]  Alan K. Davis,et al.  Patterns of Use, Acute Subjective Experiences, and Motivations for Using Synthetic Cathinones (“Bath Salts”) in Recreational Users , 2016, Journal of psychoactive drugs.

[16]  R. Glennon,et al.  Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP) , 2016, Brain Research Bulletin.

[17]  A. Reitz,et al.  Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator , 2016, Neuropharmacology.

[18]  P. Dargan,et al.  Psychosis associated with acute recreational drug toxicity: a European case series , 2016, BMC Psychiatry.

[19]  Marcia Constantinou,et al.  A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. , 2016, Forensic science international.

[20]  B. Blough,et al.  Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. , 2016, Neurotoxicology.

[21]  C. Crespi.  Flakka-Induced Prolonged Psychosis , 2016, Case reports in psychiatry.

[22]  M. Cole,et al.  Locomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology , 2016, Neuropsychopharmacology.

[23]  T. Wright,et al.  Twenty-One Cases Involving Alpha-Pyrrolidinovalerophenone (α-PVP). , 2016, Journal of analytical toxicology.

[24]  Kayla N. Ellefsen,et al.  Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases , 2016, Drug metabolism reviews.

[25]  M. Kłyś,et al.  New psychoactive substance α-PVP in a traffic accident case , 2016, Forensic Toxicology.

[26]  C. Sauer,et al.  GC-MS analysis of the designer drug α-pyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case. , 2016, Forensic science international.

[27]  J. Billieux,et al.  The Synthetic Cannabinoids Phenomenon. , 2016, Current pharmaceutical design.

[28]  B. Blough,et al.  Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys , 2016, Psychopharmacology.

[29]  A. Salomone,et al.  Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples , 2016, Analytical and Bioanalytical Chemistry.

[30]  F. Carvalho,et al.  3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions , 2015, Archives of Toxicology.

[31]  N. Moukaddam,et al.  New Drugs of Abuse and Withdrawal Syndromes. , 2015, Emergency medicine clinics of North America.

[32]  David E. Smith,et al.  The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis , 2015, Journal of psychoactive drugs.

[33]  D. Igoe,et al.  Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[34]  N. Rovina,et al.  "Bath Salts" intoxication with multiorgan failure and left-sided ischemic colitis: a case report. , 2015, Hippokratia.

[35]  M. Febo,et al.  Designer Drugs: A Synthetic Catastrophe , 2015, Journal of reward deficiency syndrome.

[36]  T. Dickerson,et al.  In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats , 2015, Psychopharmacology.

[37]  M. Sykutera,et al.  A Fatal Case of Pentedrone and α-Pyrrolidinovalerophenone Poisoning. , 2015, Journal of analytical toxicology.

[38]  L. Karila,et al.  [Novel psychoactive substances: a review]. , 2015, Presse medicale.

[39]  J. A. Hopper,et al.  Designer drugs 2015: assessment and management , 2015, Addiction Science & Clinical Practice.

[40]  M. Liechti,et al.  Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones , 2015, European Neuropsychopharmacology.

[41]  I. Ojanperä,et al.  Fatal poisoning in drug addicts in the Nordic countries in 2012. , 2015, Forensic science international.

[42]  Laurent Karila,et al.  Synthetic Cathinones: A New Public Health Problem , 2015, Current neuropharmacology.

[43]  J. Laplanche,et al.  [Novel psychoactive substances: a review]. , 2015, Presse medicale.

[44]  M. Levine,et al.  Acute Methylenedioxypyrovalerone Toxicity , 2014, Journal of Medical Toxicology.

[45]  B. Blough,et al.  Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV) , 2014, Neuropharmacology.

[46]  F. Couper,et al.  Suspected impaired driving case involving α-pyrrolidinovalerophenone, methylone and ethylone. , 2014, Journal of analytical toxicology.

[47]  Laurent Karila,et al.  New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. , 2014, Current pharmaceutical design.

[48]  J. Zawilska.  Mephedrone and other cathinones , 2014, Current opinion in psychiatry.

[49]  D. Rusyniak,et al.  Synthetic cathinones ("bath salts"). , 2014, The Journal of emergency medicine.

[50]  Ken-ichi Yoshida,et al.  Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. , 2014, International journal of cardiology.

[51]  G. Hanson,et al.  Bath salts and synthetic cathinones: an emerging designer drug phenomenon. , 2014, Life sciences.

[52]  S. Numazawa,et al.  New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. , 2014, The Journal of toxicological sciences.

[53]  R. Glennon.  Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. , 2014, Advances in pharmacology.

[54]  J. Zawilska,et al.  Designer cathinones--an emerging class of novel recreational drugs. , 2013, Forensic science international.

[55]  Vijay K. Ramu,et al.  “Bath salts” induced severe reversible cardiomyopathy , 2013, The American journal of case reports.

[56]  B. Tokarczyk,et al.  Analysis of MDPV in blood--determination and interpretation. , 2013, Journal of analytical toxicology.

[57]  Heather M. Antonides,et al.  Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. , 2013, Journal of analytical toxicology.

[58]  Kurt R. Lehner,et al.  Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products , 2013, Neuropsychopharmacology.

[59]  L. Velez,et al.  Two cases of disseminated intravascular coagulation due to "bath salts" resulting in fatalities, with laboratory confirmation. , 2013, The American journal of emergency medicine.

[60]  R. Glennon,et al.  Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter , 2013, Psychopharmacology.

[61]  Kurt R. Lehner,et al.  Psychoactive "bath salts": not so soothing. , 2013, European journal of pharmacology.

[62]  J. Ballenger.  Serotonin Syndrome Associated With MDPV Use: A Case Report , 2013 .

[63]  T. Penders,et al.  Excited delirium following use of synthetic cathinones (bath salts). , 2012, General hospital psychiatry.

[64]  W. Lowenstein,et al.  Diagnosis and consequences of cocaine addiction. , 2012, Current medicinal chemistry.

[65]  M. Coppola,et al.  3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. , 2012, Toxicology letters.

[66]  Brittany L. Murray,et al.  Death Following Recreational Use of Designer Drug “Bath Salts” Containing 3,4-Methylenedioxypyrovalerone (MDPV) , 2012, Journal of Medical Toxicology.

[67]  P. Kyle,et al.  Illicit bath salts: not for bathing. , 2011, Journal of the Mississippi State Medical Association.

[68]  Lewis S. Nelson,et al.  The Toxicology of Bath Salts: A Review of Synthetic Cathinones , 2011, Journal of Medical Toxicology.

[69]  L. Karila,et al.  GHB and synthetic cathinones: clinical effects and potential consequences. , 2011, Drug testing and analysis.

[70]  J. Deschamps,et al.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. , 2006, Journal of medicinal chemistry.

[71]  E. Vuori,et al.  Fatal poisoning in drug addicts in the Nordic countries. , 2001, Forensic science international.